Syndax Pharmaceuticals, Inc.
SNDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSyndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. At a $1.84B market cap, Syndax Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Market Cap
$1.84B
Beta
0.37
P/E (TTM)
—
P/E (Fwd)
-25.20
EPS (TTM)
$-2.51
EPS (Fwd)
$-0.82
ROE
-255.9%
ROA
-18.7%
Cash
$554.3M
Total Debt
$589.4M
Free CF
-$150.1M
52W Change
29.1%
Annual Financials
Cash vs Debt
Where SNDX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SNDX finished 1.98% below its 150-day moving average ($21.20) and 0.76% below its 200-day moving average ($20.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNDX overbought or oversold?
At the September 3, 2026 close, SNDX's RSI(14) was 64.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Syndax Pharmaceuticals, Inc. carries $589.4M in total debt against $554.3M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$150.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -255.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Syndax Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Syndax Pharmaceuticals, Inc. and its sector.